Barclays
CLVS

Barclays’s Clovis Oncology, Inc. CLVS Stock Holding History

Barclays’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-8,700
Closed -$24K – 5795
2021
Q4 		$24K Hold
8,700
– – ﹤0.01% 3937
2021
Q3 		$39K Hold
8,700
– – ﹤0.01% 4172
2021
Q2 		$50K Hold
8,700
– – ﹤0.01% 4134
2021
Q1 		$61K Sell
8,700
-43,200
-83% -$290K ﹤0.01% 4166
2020
Q4 		$249K Sell
51,900
-15,800
-23% -$79.9K ﹤0.01% 3643
2020
Q3 		$394K Sell
67,700
-4,700
-6% -$28.1K ﹤0.01% 3409
2020
Q2 		$488K Sell
72,400
-27,600
-28% -$209K ﹤0.01% 3357
2020
Q1 		$636K Sell
100,000
-53,400
-35% -$428K ﹤0.01% 3387
2019
Q4 		$1.6M Buy
153,400
+105,800
+222% +$769K ﹤0.01% 3225
2019
Q3 		$187K Buy
47,600
+26,600
+127% +$215K ﹤0.01% 5020
2019
Q2 		$312K Sell
21,000
-24,500
-54% -$443K ﹤0.01% 4738
2019
Q1 		$1.13M Buy
45,500
+9,300
+26% +$233K ﹤0.01% 3283
2018
Q4 		$650K Sell
36,200
-3,100
-8% -$63.3K ﹤0.01% 3564
2018
Q3 		$1.15M Sell
39,300
-37,300
-49% -$1.44M ﹤0.01% 3492
2018
Q2 		$3.48M Buy
76,600
+22,700
+42% +$1.1M ﹤0.01% 2041
2018
Q1 		$2.85M Sell
53,900
-48,400
-47% -$2.82M ﹤0.01% 2120
2017
Q4 		$6.96M Sell
102,300
-25,900
-20% -$1.81M 0.01% 1414
2017
Q3 		$10.6M Sell
128,200
-18,200
-12% -$1.44M 0.01% 1023
2017
Q2 		$13.7M Buy
146,400
+109,900
+301% +$6.72M 0.01% 796
2017
Q1 		$2.32M Buy
36,500
+3,000
+9% +$182K ﹤0.01% 1948
2016
Q4 		$1.49M Buy
33,500
+12,000
+56% +$422K ﹤0.01% 2381
2016
Q3 		$775K Sell
21,500
-22,500
-51% -$483K ﹤0.01% 2865
2016
Q2 		$604K Sell
44,000
-5,000
-10% -$73.1K ﹤0.01% 3048
2016
Q1 		$931K Buy
+49,000
New +$1.04M ﹤0.01% 2582
2014
Q3 		– Sell
-175,400
Closed -$7.19M – 7878
2014
Q2 		$7.19M Buy
+175,400
New +$9.03M 0.01% 1418

Other funds holding CLVS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CAS
Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return
CASC
Coppell Advisory Solutions Corp Coppell, Texas $531M AUM
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
FFWM
Future Financial Wealth Management Cincinnati, Ohio $155M AUM 13% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Barclays's CLVS Position: Q4 2022 in Review

Barclays sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 132,775 shares — an estimated $158K sold.

Barclays first reported a position in CLVS in Q2 2013 and held it in 38 quarters. The position peaked at $13M in Q4 2016. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

  • Barclays reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
  • Barclays sold 132,775 Clovis Oncology, Inc. shares in Q4 2022, an estimated $158K.
  • Barclays first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 38 quarters.
  • Barclays's Clovis Oncology, Inc. position peaked at $13M in Q4 2016.
  • 15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Barclays's 13F filing for Q4 2022, filed 13 Feb 2023.